SMARCA2 and lung carcinoma: Furthermore, HDACi, a class of anti-cancer drugs that blocks the deacetylation of chromatin and other cellular substrates involved in cancer initiation and progression74,75, has also been shown to reactivate SMARCA2 expression in SCCOHT and lung cancer cells17,76,77.